Single Nucleotide Polymorphisms As Prognostic and Predictive Biomarkers in Renal Cell Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Jan 2

PMID 29290970

Citations 10

Authors

Carmen Garrigos

Marta Espinosa

Ana Salinas

Ignacio Osman

Rafael Medina

Miguel Taron

Sonia Molina-Pinelo

Ignacio Duran

Affiliations

Soon will be listed here.

Abstract

Despite major advances in the knowledge of the molecular basis of renal cell carcinoma, prognosis is still defined using clinical and pathological parameters. Moreover, no valid predictive biomarkers exist to help us selecting the best treatment for each patient. With these premises, we aimed to analyse the expression and to determine the prognostic and predictive value of 64 key single nucleotide polymorphisms in 18 genes related with angiogenesis or metabolism of antiangiogenics in two cohorts of patients with localized and advanced renal cell cancer treated at our institution. The presence of the selected single nucleotide polymorphisms was correlated with clinical features, disease free survival, overall survival and response rate. In patients with localized renal cell cancer, 5 of these polymorphisms in 3 genes involved in angiogenesis predicted for worse disease free survival (VEGFR2: rs10013228; PDGFRA: rs2228230) or shorter overall survival (VEGFR2: rs10013228; VEGFR3: rs6877011, rs307826) ( < 0.05). Rs2071559 in VEGFR2 showed a protective effect ( = 0.01). In the advanced setting, 5 SNPs determined inferior overall survival (IL8: rs2227543, PRKAR1B: rs9800958, PDGFRB: rs2302273; = 0.05) or worse response rate (VEGFA: rs699947, rs3025010 ≤ 0.01)). Additionally 1 single nucleotide polymorphism in VEGFB predicted for better response rate rs594942 ( = 0.03). Genetic analysis of renal cell carcinoma patients might provide valuable prognostic/predictive information. A set of SNPs in genes critical to angiogenesis and metabolism of antiangiogenics drugs seem to determine post-surgical outcomes and treatment response in our series.

Citing Articles

Ensemble learning-based predictor for driver synonymous mutation with sequence representation.

Bi C, Shi Y, Xia J, Liang Z, Wu Z, Xu K PLoS Comput Biol. 2025; 21(1):e1012744.

PMID: 39761306 PMC: 11737855. DOI: 10.1371/journal.pcbi.1012744.

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) rs2071559 Gene Polymorphism and the Risk of Gliomas: A Systematic Review and Meta-Analysis.

Prasetiyo P, Wahjoepramono E J Clin Med. 2024; 13(15).

PMID: 39124599 PMC: 11313419. DOI: 10.3390/jcm13154332.

Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Kaissarian N, Meyer D, Kimchi-Sarfaty C J Natl Cancer Inst. 2022; 114(8):1072-1094.

PMID: 35477782 PMC: 9360466. DOI: 10.1093/jnci/djac090.

Germline Variants in Angiogenesis-Related Genes Contribute to Clinical Outcome in Head and Neck Squamous Cell Carcinoma.

Butkiewicz D, Gdowicz-Klosok A, Krzesniak M, Rutkowski T, Lasut-Szyszka B, Skladowski K Cancers (Basel). 2022; 14(7).

PMID: 35406617 PMC: 8997703. DOI: 10.3390/cancers14071844.

Computational and structural based approach to identify malignant nonsynonymous single nucleotide polymorphisms associated with CDK4 gene.

Islam R, Rahaman M, Hoque H, Hasan N, Prodhan S, Ruhama A PLoS One. 2021; 16(11):e0259691.

PMID: 34735543 PMC: 8568134. DOI: 10.1371/journal.pone.0259691.

References

van der Zanden L, Vermeulen S, Oskarsdottir A, Maurits J, Diekstra M, Ambert V . Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity. Urol Oncol. 2017; 35(8):529.e9-529.e16. DOI: 10.1016/j.urolonc.2017.03.009. View

Diekstra M, Swen J, Boven E, Castellano D, Gelderblom H, Mathijssen R . CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015; 68(4):621-9. DOI: 10.1016/j.eururo.2015.04.018. View

Cohen H, McGovern F . Renal-cell carcinoma. N Engl J Med. 2005; 353(23):2477-90. DOI: 10.1056/NEJMra043172. View

Apellaniz-Ruiz M, Diekstra M, Roldan J, Boven E, Castellano D, Gelderblom H . Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenet Genomics. 2017; 27(6):227-231. DOI: 10.1097/FPC.0000000000000280. View

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F . Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1814-23. PMC: 5024539. DOI: 10.1056/NEJMoa1510016. View

Heidaran M, PIERCE J, Yu J, Lombardi D, Artrip J, Fleming T . Role of alpha beta receptor heterodimer formation in beta platelet-derived growth factor (PDGF) receptor activation by PDGF-AB. J Biol Chem. 1991; 266(30):20232-7. View

Diekstra M, Fritsch A, Kanefendt F, Swen J, Moes D, Sorgel F . Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer. CPT Pharmacometrics Syst Pharmacol. 2017; 6(9):604-613. PMC: 5613186. DOI: 10.1002/psp4.12210. View

Saenz-Lopez P, Vazquez F, Cozar J, Carretero R, Garrido F, Ruiz-Cabello F . VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol. 2012; 74(1):98-103. DOI: 10.1016/j.humimm.2012.10.014. View

Pavlovich C, Schmidt L . Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer. 2004; 4(5):381-93. DOI: 10.1038/nrc1364. View

10.

de Mello R, Ferreira M, Soares-Pires F, Costa S, Cunha J, Oliveira P . The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer. PLoS One. 2013; 8(9):e72373. PMC: 3765163. DOI: 10.1371/journal.pone.0072373. View

11.

van der Veldt A, Eechoute K, Gelderblom H, Gietema J, Guchelaar H, van Erp N . Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2010; 17(3):620-9. DOI: 10.1158/1078-0432.CCR-10-1828. View

12.

Zheng Y, Zhan M, Zhao W, Liu B, Huang J, He X . The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Med Oncol. 2014; 31(10):209. DOI: 10.1007/s12032-014-0209-z. View

13.

Crawford D, Nickerson D . Definition and clinical importance of haplotypes. Annu Rev Med. 2005; 56:303-20. DOI: 10.1146/annurev.med.56.082103.104540. View

14.

Sakurai T, Kudo M . Signaling pathways governing tumor angiogenesis. Oncology. 2012; 81 Suppl 1:24-9. DOI: 10.1159/000333256. View

15.

Lambrechts D, Thienpont B, Thuillier V, Sagaert X, Moisse M, Peuteman G . Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Br J Cancer. 2015; 113(7):1027-34. PMC: 4651136. DOI: 10.1038/bjc.2015.329. View

16.

Wu L, Xie H, Zhou L, Yang Z, Zhang F, Zheng S . A single nucleotide polymorphism in the vascular endothelial growth factor gene is associated with recurrence of hepatocellular carcinoma after transplantation. Arch Med Res. 2010; 40(7):565-70. DOI: 10.1016/j.arcmed.2009.07.011. View

17.

Motzer R, Rini B, Mcdermott D, Redman B, Kuzel T, Harrison M . Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2014; 33(13):1430-7. PMC: 4806782. DOI: 10.1200/JCO.2014.59.0703. View

18.

Garcia-Donas J, Esteban E, Leandro-Garcia L, Castellano D, Del Alba A, Climent M . Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011; 12(12):1143-50. DOI: 10.1016/S1470-2045(11)70266-2. View

19.

Gnarra J, Tory K, Weng Y, Schmidt L, Wei M, Li H . Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994; 7(1):85-90. DOI: 10.1038/ng0594-85. View

20.

Diekstra M, Liu X, Swen J, Boven E, Castellano D, Gelderblom H . Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2015; 71(12):1477-84. PMC: 4643117. DOI: 10.1007/s00228-015-1935-7. View